Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure-Reference-Cited by-同舟云学术

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

Published:2020-09 Issue:5 Volume:16 Page:345-352
ISSN:1699-258X
Container-title:Reumatología Clínica
language:en
Short-container-title:Reumatología Clínica

Author:

Blanco Francisco J.,Rubio-Romero Esteban,Sanmartí Raimon,Díaz-Torné César,Talavera Pablo,Dunkel Jochen,Naredo Esperanza

Funder

UCB Pharma

Publisher

Elsevier BV

Subject

Rheumatology

Reference34 articles.

1. Epidemiology and burden of illness of rheumatoid arthritis;Kvien;Pharmacoeconomics,2004

2. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials;Salliot;Ann Rheum Dis,2009

3. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients];Gomez Reino;Reumatol Clin,2011

4. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study;Weinblatt;Rheumatology (Oxford),2012

5. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice;Bombardieri;Rheumatology,2007

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study;Rheumatology and Therapy;2024-08-23